0GHZ Stock Overview
A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xspray Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 40.75 |
| 52 Week High | SEK 77.70 |
| 52 Week Low | SEK 34.90 |
| Beta | 0.85 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | 7.81% |
| 3 Year Change | -34.85% |
| 5 Year Change | n/a |
| Change since IPO | -47.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GHZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 2.0% | 1.6% |
| 1Y | 7.8% | -23.2% | 4.6% |
Return vs Industry: 0GHZ exceeded the UK Biotechs industry which returned -23.2% over the past year.
Return vs Market: 0GHZ exceeded the UK Market which returned 4.6% over the past year.
Price Volatility
| 0GHZ volatility | |
|---|---|
| 0GHZ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0GHZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0GHZ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 24 | Per Andersson | www.xspraypharma.com |
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.
Xspray Pharma AB (publ) Fundamentals Summary
| 0GHZ fundamental statistics | |
|---|---|
| Market cap | SEK 1.60b |
| Earnings (TTM) | -SEK 258.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.2x
P/E RatioIs 0GHZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GHZ income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 258.05m |
| Earnings | -SEK 258.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | -6.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0GHZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 23:39 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xspray Pharma AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dan Akschuti | Pareto Securities |
| Filip Einarsson | Redeye |